Guggenheim reiterates Buy on Phathom stock after FDA grants exclusivity

Guggenheim reaffirmed its Buy rating and $12 price target on Phathom Pharmaceuticals (PHAT) after the FDA granted Voquezna tablets 10-year New Chemical Entity exclusivity, extending protection until 2032 and addressing Phathom's Citizen Petition. This exclusivity is expected to remove a stock overhang and attract investors. Q1 2025 EPS of -1.07 USD beat estimates, and revenue reached 28.5 million USD, also exceeding forecasts; Phathom is implementing cost-cutting measures to achieve profitability by 2026.

Analysis

Phathom Pharmaceuticals (NASDAQ: PHAT) has received a significant positive catalyst with the U.S. Food and Drug Administration (FDA) granting 10-year New Chemical Entity (NCE) exclusivity for its Voquezna tablets, extending market protection until May 2032. This regulatory decision, resolving Phathom's Citizen Petition from December 2024 concerning Orange Book listings, is expected to alleviate a major stock overhang and potentially attract new investors, as noted by Guggenheim analysts who reaffirmed their Buy rating and $12.00 price target. The stock has already seen a 10.35% gain over the past week. Further bolstering investor confidence, Phathom reported better-than-expected first-quarter 2025 earnings, with an EPS of -$1.07 (beating -$1.11 projected) and revenue of $28.5 million (exceeding $27.75 million forecast). Concurrently, the company, under its new CEO, is implementing cost-reduction measures targeting profitability by 2026. While Phathom demonstrates strong liquidity with a current ratio of 3.58, it continues to operate with significant debt. Other analyst firms share a positive outlook; Stifel maintained a Buy rating, and H.C. Wainwright, while adjusting its price target from $28.00 to $20.00, reiterated a Buy rating, citing confidence in Phathom's strategic pivot to leverage its salesforce and GI specialist channels. Guggenheim’s net present value analysis suggests a fair value for PHAT stock in the $12-14 range, reinforcing the positive sentiment.

Key Decisions for Investors

• Investors should recognize the enhanced commercial outlook for Voquezna following its 10-year FDA exclusivity and Phathom's strong Q1 2025 financial performance, which underpins reaffirmed Buy ratings and a $12-14 fair value estimate from Guggenheim.
• Careful monitoring of Phathom's execution on its announced cost-reduction initiatives and progress towards the 2026 profitability target is crucial, particularly in light of its significant existing debt.
• The effectiveness of Phathom's revised commercial strategy, emphasizing its salesforce and GI specialist channels instead of direct-to-consumer marketing, should be assessed as a key determinant for sustained growth and market share capture in the gastrointestinal treatment market.